-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_disposition-comments.pdf
September 01, 2011 - We believe
this rational is clearly described in the
Introduction at the end of the “Patient
Populations … BA 25) has substantial
efficacy in experimental studies, yet this is not described. … The characteristics of the studies are clearly described
and key messages are stated explicitly and … The
limitations of the review/studies are described adequately. … described and not a part of eligibility criteria
for study).
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-artery-disease-treatment_disposition-comments.pdf
May 29, 2013 - The
search, inclusion and exclusion criteria are well
described. … Peer Reviewer 3 Methods Very sound methods that are clearly described. Thank you. … Outcome measures are appropriate and described
adequately. … TEP Member 4 Results Characteristics of the studies are clearly described in
the report and (in a more … The
numerous and serious limitations of the studies/review
are clearly described (best in Executive
-
effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
January 01, 2011 - Dia 1
1
Integrating stakeholder preferences in
comparative effectiveness research
using multi-criteria decision analysis
(MCDA) and Conjoint Analysis (CA)
Maarten J. IJzerman, PhD
Professor and chair, department Health Technology &
Services Research
m.j.ijzerman@utwente.nl
Multiple endpoints in …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
August 07, 2018 - There are some issues with the search strategy as
described in the general comments attachment. … In several locations in the document, study findings
are described as "mixed" but no other details or … Currently, the study is
described in one part of the document but not others. … Results –
Overall
Peer Reviewer
#5
The included studies are well-described and the informative … “Handling
of data from missing persons not described” Refer to figure 1.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-195-disposition-comments-uterine-fibroids.pdf
December 14, 2017 - We revised SOE here and later in the report as described below in the
reply to comments in the more … Ullipristal is described
as follows: Ulipristal acetate (Ella®, Esmya®) is a selective
progesterone … We reported potential harms as described in the included studies (now
including Donnez). … We reported potential harms as described in the included studies (now
including Donnez). … The characteristics of the studies are
clearly described, with key messages clearly communicated.
-
effectivehealthcare.ahrq.gov/sites/default/files/palliative-care-tools-disposition.pdf
May 04, 2017 - of
relevant issues and gaps”
24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their
opinions on all aspects of the project given their role as
described … clinical assessment, QI, Research, Accountability)
The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in
the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as
described in the definition in the beginning
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/palliative-care-tools-disposition.pdf
May 04, 2017 - of
relevant issues and gaps”
24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their
opinions on all aspects of the project given their role as
described … clinical assessment, QI, Research, Accountability)
The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in
the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as
described in the definition in the beginning
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-201-indoor-allergen-asthma-disposition-comments.pdf
February 15, 2018 - Thus,
we encourage the Agency to finalize this Draft Report
with the suggested modifications described … All of these approaches are
now described more fully in the
Results, and and the limitations of our … As described in the Methods, we used
AHRQ EPC methods to guide our
assessment of the body of evidence … Study characteristics are well described.
Thank you. … All of these approaches are
not described more fully in the
Results, and the limitations of our
analysis
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-risk-drugs-protocol.pdf
July 27, 2023 - • Unspecified study designs or comparison
group not described.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
December 20, 2018 - Peer
Reviewer #1
Evidence
Summary
ES-3, lines 26-32 Clarify all DAS28 scores described are
baseline … The ranges of DAS28 scores described for each drug
category capture both mean and median values of our … If one changes and
others do not, this is described in the detailed results. … Peer
Reviewer #3
Introduction Nulliparity was described as a risk factor for RA (page 1, line
20) … Peer
Reviewer #3
Methods Throughout the document, studies involving MTX are
described and results
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-comments_0.pdf
October 11, 2019 - page 22+): The content is not linked to KQ nor
SOE descriptions; suggest replacing with the table
described
-
effectivehealthcare.ahrq.gov/sites/default/files/mccullough.pdf
January 01, 2011 - McCullough
Slide
1: An Ethical Framework for Supporting
Shared Decision Making
When Clinical
Evidence is Low
Laurence B. McCullough, Ph.D.
Dalton Tomlin Chair in Medical Ethics and Health Policy
Associate Director for Education
Center for Medical Ethics and
…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/multiple-sclerosis_research-protocol.pdf
December 17, 2013 - review based on the PICOTS framework outlined in
Section II and the study-specific inclusion criteria described … www.effectivehealthcare.ahrq.gov
Published online: December 17, 2013
9
results to planned analysis described … in trial registries and/or the methodology section of
the publication as described in a recent AHRQ
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/weight-loss-surgery_research-protocol.pdf
December 14, 2010 - Population(s):
Demographic subsets of the populations described in KQ1. … for this Comparative Effectiveness
Review, with the five key questions depicted within the context described … Studies will be included that address the populations, interventions, comparators,
and outcomes described
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/labor-nitrous-oxide_research-protocol.pdf
August 24, 2011 - used nitrous oxide (likely an overestimate considering how few U.S. facilities offer this
method as described … Bishop has briefly described the UCSF practices in ―Administration
of Nitrous Oxide in Labor: Expanding … (e.g., Nitronox) is the most common
method of nitrous oxide administration for labor pain relief described
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
July 01, 2010 - We
categorized patients by medication use and by their first fill-date of exenatide, and described the … For descriptive purposes, we reported the means and
percentages of the variables described above. … After creating
the cohort, as described in the methods, we studied the 3,225 patients who filled exenatide
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/pediatric-ehr_research-protocol.pdf
January 01, 2014 - policy makers, and professional organizations such as the American Academy
of Pediatrics (AAP) have described … meet pediatric functionality and workflow demands could be potentially dangerous.10 Some studies have
described … Healthcare Research and Quality (AHRQ),41 Health Level 7 (HL7) International,42 and the
AAP3 have described
-
effectivehealthcare.ahrq.gov/sites/default/files/study-design-considerations-chapter-2.pptx
January 01, 2013 - Commonly used comparative effectiveness research study designs are described, and key design features … exposure classification (heart transplant or not) should not be attributed to the heart transplant and is described … Approaches to empirical identification of confounders should be described if planned.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/quality-gap-palliative-hospice_executive.pdf
October 01, 2012 - We included 90 studies described
in 96 articles in the review (Figure B). … We described the
information abstracted in a systematic manner but did not
conduct any meta-analyses … Coordination of Care, and Transitions
Key Question 1a: Evidence About Target
We found 23 studies described
-
effectivehealthcare.ahrq.gov/sites/default/files/module-iii-points-of-engagement-in-the-ehc-program.pdf
May 29, 2025 - Module III: Points of Engagement in the EHC Program
…